Are antipsychotics effective for the treatment of anorexia nervosa? Results from a systematic review and meta-analysis

Journal of Clinical Psychiatry

Volumn 73, Issue 6, 2012, Pages

  Kishi, Taro ^a,b   Kafantaris, Vivian ^a,c,d,e   Sunday, Suzanne ^d,e   Sheridan, Eva M ^a   Correll, Christoph U ^a,c,d,e  

^a Northwell Health   (United States)

^b FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^e DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; GLUCOSE; MULTIVITAMIN; NEUROLEPTIC AGENT; OLANZAPINE; PIMOZIDE; PLACEBO; QUETIAPINE; RISPERIDONE; SULPIRIDE; ZINC;

ADOLESCENT; ADULT; AKATHISIA; ANOREXIA NERVOSA; ANXIETY; ARTICLE; BODY BUILD; BODY MASS; BODY WEIGHT; CHILD; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DROWSINESS; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FEEDING BEHAVIOR; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PRIORITY JOURNAL; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHOOL CHILD; SEDATION; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84863540169     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.12r07691     Document Type: Article

References (53)

1. Birmingham CL, Touyz S, Harbottle J. Are anorexia nervosa and bulimia nervosa separate disorders? challenging the "transdiagnostic" theory of eating disorders. Eur Eat Disord Rev. 2009;17(1):2-13. doi:10.102/erv.896 PubMed
2. Zipfel S, Löwe B, Reas DL, et al. Long-term prognosis in anorexia nervosa: lessons from a 21-year follow-up study. Lancet. 2000;355(9205):721-722. doi:10.1016/S0140-6736(9)05363-5 PubMed (Pubitemid 30107630)
3. Mattar L, Huas C, Duclos J, et al. Relationship between malnutrition and depression or anxiety in anorexia nervosa: a critical review of the literature. J Affect Disord. 2011;132(3):311-318. doi:10.1016/j.jad.2010.09.014 PubMed
4. Kaye WH, Fudge JL, Paulus M. New insights into symptoms and neurocircuit function of anorexia nervosa. Nat Rev Neurosci. 2009;10(8):573-584. doi:10.1038/nrn2682 PubMed
5. De Hert M, Correll CU, Bobes J, et al. Physical illness in patients with severe mental disorders, 1: prevalence, impact of medications and disparities in health care. World Psychiatry. 2011;10(1):52-77. PubMed
6. Allison DB, Newcomer JW, Dunn AL, et al. Obesity among those with mental disorders: a National Institute of Mental Health meeting report. Am J Prev Med. 2009;36(4):341-350. doi:10.1016/j.amepre.208.1.020 PubMed
7. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(suppl 1):1-93. doi:10.2165/023210-2051901-01 PubMed (Pubitemid 40677047)
8. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry. 2009;166(9):980-991. doi:10.176/api.ajp.209.09030312 PubMed
9. Komossa K, Depping AM, Meyer M, et al. Second-generation antipsychotics for obsessive compulsive disorder. Cochrane Database Syst Rev. 2010;(12):CD008141. PubMed
10. Komossa K, Depping AM, Gaudchau A, et al. Second-generation antipsychotics for major depressive disorder and dysthymia. Cochrane Database Syst Rev. 2010;(12):CD008121. PubMed
11. Depping AM, Komossa K, Kissling W, et al. Second-generation antipsychotics for anxiety disorders. Cochrane Database Syst Rev. 2010;(12):CD008120. PubMed
12. Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009;302(16):1765-1773. doi:10.101/jama.209.1549 PubMed
13. Foley DL, Morley KI. Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis. Arch Gen Psychiatry. 2011;68(6):609-616. doi:10.101/archgenpsychiatry.201.2 PubMed
14. Correll CU, Lencz T, Malhotra AK. Antipsychotic drugs and obesity. Trends Mol Med. 2011;17(2):97-107. doi:10.1016/j.molmed.2010.10.010 PubMed
15. De Hert M, Detraux J, van Winkel R, et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2011;8(2):114-126. PubMed
16. Attia E, Kaplan AS, Walsh BT, et al. Olanzapine versus placebo for outpatients with anorexia nervosa. Psychol Med. 2011;41(10):2177-2182. doi:10.1017/S03291710390 PubMed
17. Bissada H, Tasca GA, Barber AM, et al. Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2008;165(10):1281-1288. doi:10.176/api.ajp.208.0712190 PubMed
18. Brambilla F, Garcia CS, Fassino S, et al. Olanzapine therapy in anorexia nervosa: psychobiological effects. Int Clin Psychopharmacol. 2007;22(4):197-204. doi:10.1097/YIC.0b013e328080ca31 PubMed (Pubitemid 46801942)
19. Kafantaris V, Leigh E, Hertz S, et al. A placebo-controlled pilot study of adjunctive olanzapine for adolescents with anorexia nervosa. J Child Adolesc Psychopharmacol. 2011;21(3):207-212. doi:10.1089/cap.2010.0139 PubMed
20. Court A, Mulder C, Kerr M, et al. Investigating the effectiveness, safety and tolerability of quetiapine in the treatment of anorexia nervosa in young people: a pilot study. J Psychiatr Res. 2010;44(15):1027-1034. doi:10.1016/j.jpsychires.2010.03.01 PubMed
21. Hagman J, Gralla J, Sigel E, et al. A double-blind, placebo-controlled study of risperidone for the treatment of adolescents and young adults with anorexia nervosa: a pilot study. J Am Acad Child Adolesc Psychiatry. 2011;50(9):915-924. doi:10.1016/j.jac.201.06.09 PubMed
22. Cohn LD, Becker BJ. How meta-analysis increases statistical power. Psychol Methods. 2003;8(3):243-253. doi:10.1037/1082-989X.8.3.243 PubMed (Pubitemid 37268945)
23. Vandereycken W. Neuroleptics in the short-term treatment of anorexia nervosa: a double-blind placebo-controlled study with sulpiride. Br J Psychiatry. 1984;144(3):288-292. doi:10.192/bjp.14.3.28 PubMed (Pubitemid 14159403)
24. Mazure CM, Halmi KA, Sunday SR, et al. The Yale-Brown-Cornell Eating Disorder Scale: development, use, reliability and validity. J Psychiatr Res. 1994;28(5):425-445. doi:10.1016/02-3956(94)902-7 PubMed
25. Garner DM. Eating Disorder Inventory-2: Professional Manual. Odessa, FL: Psychological Assessment Resources; 1991.
26. Slade PD. A short anorexic behaviour scale. Br J Psychiatry. 1973;122(566):83-85. doi:10.192/bjp.12.1.83 PubMed
27. Cooper PJ, Taylor MJ, Cooper Z, et al. The development and validation of the Body Shape Questionnaire. Int J Eat Disord. 1987;6(4):485-494. doi:10.102/1098-108X(198707)6:4<485:AID-EAT26060405>3.0.CO;2-O
28. Fairburn CG, Cooper Z. The Eating Disorder Examination. In: Fairburn CG, Wilson GT, eds. Binge Eating: Nature, Assessment, and Treatment. New York, NY: Guilford Press; 1993:317-360.
29. Williams JB. A structured interview guide for the Hamilton Depression Rating Scale. Arch Gen Psychiatry. 1988;45(8):742-747. doi:10.101/archpsyc.198. 01803205807 PubMed
30. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4(6):561-571. doi:10.101/archpsyc.1961. 017101203104 PubMed
31. Morey LC. Personality Assessment Inventory (PAI): Professional Manual. Odessa, FL: Psychological Assessment Resources; 1991.
32. Roberts RE, Vernon SW. The Center for Epidemiologic Studies Depression Scale: its use in a community sample. Am J Psychiatry. 1983;140(1):41-46. PubMed (Pubitemid 13221717)
33. Beck AT, Epstein N, Brown G, et al. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988;56(6):893-897. doi:10.1037/02-06X.56.6.893 PubMed (Pubitemid 19008360)
34. Watson D, Weber K, Assenheimer JS, et al. Testing a tripartite model, 1: evaluating the convergent and discriminant validity of anxiety and depression symptom scales. J Abnorm Psychol. 1995;104(1):3-14. doi:10.1037/021-843X.104.1.3 PubMed
35. March JS, Parker JD, Sullivan K, et al. The Multidimensional Anxiety Scale for Children (MASC): factor structure, reliability, and validity. J Am Acad Child Adolesc Psychiatry. 1997;36(4):554-565. doi:10.1097/04583-197040-019 PubMed (Pubitemid 27149194)
36. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188. doi:10.1016/0197-2456(86)9046-2 PubMed (Pubitemid 17189972)
37. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-560. doi:10.136/bmj.327.7414.57 PubMed (Pubitemid 37088507)
38. Court A, Mulder C, Hetrick SE, et al. What is the scientific evidence for the use of antipsychotic medication in anorexia nervosa? Eat Disord. 2008;16(3):217-223. doi:10.1080/10640260802016761 PubMed (Pubitemid 351638549)
39. McKnight RF, Park RJ. Atypical antipsychotics and anorexia nervosa: a review. Eur Eat Disord Rev. 2010;18(1):10-21. doi:10.102/erv.98 PubMed
40. Vandereycken W, Pierloot R. Pimozide combined with behavior therapy in the short-term treatment of anorexia nervosa: a double-blind placebocontrolled cross-over study. Acta Psychiatr Scand. 1982;66(6):445-450. doi:10.1/j.160-047. 1982.tb04501.x PubMed (Pubitemid 13242401)
41. Coccurello R, Moles A. Potential mechanisms of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design. Pharmacol Ther. 2010;127(3):210-251. doi:10.1016/j. pharmthera.2010.04.08 PubMed
42. Rummel-Kluge C, Komossa K, Schwarz S, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2010;123(2-3):225-233. doi:10.1016/j.schres.2010.07.012 PubMed
43. Brambilla F, Monteleone P, Maj M. Olanzapine-induced weight gain in anorexia nervosa: involvement of leptin and ghrelin secretion? Psychoneuroendocrinology. 2007;32(4):402-406. doi:10.1016/j.psyneuen.207.02.05 PubMed (Pubitemid 46617784)
44. Sunday SR, Halmi KA. Energy intake and body composition in anorexia and bulimia nervosa. Physiol Behav. 2003;78(1):11-17. doi:10.1016/S031-9384(02)0879- X PubMed (Pubitemid 36110547)
45. Gustafsson SA, Edlund B, Davén J, et al. How to deal with sociocultural pressures in daily life: reflections of adolescent girls suffering from eating disorders. J Multidiscip Healthc. 2011;4:103-110. doi:10.2147/JMDH.S17319 PubMed
46. Simon V, van Winkel R, De Hert M. Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? a literature review. J Clin Psychiatry. 2009;70(7):1041-1050. doi:10.408/JCP.08r04392 PubMed
47. Harshbarger JL, Ahlers-Schmidt CR, Mayans L, et al. Pro-anorexia websites: what a clinician should know. Int J Eat Disord. 2009;42(4):367-370. doi:10.102/eat.20608 PubMed
48. Sim LA, McAlpine DE, Grothe KB, et al. Identification and treatment of eating disorders in the primary care setting. Mayo Clin Proc. 2010;85(8):746-751. doi:10.4065/mcp.2010.070 PubMed
49. Fisher CA, Hetrick SE, Rushford N. Family therapy for anorexia nervosa. Cochrane Database Syst Rev. 2010;(4):CD004780. PubMed
50. Hartmann A, Weber S, Herpertz S, et al German Treatment Guideline Group for Anorexia Nervosa. Psychological treatment for anorexia nervosa: a meta-analysis of standardized mean change. Psychother Psychosom. 2011;80(4):216-226. doi:10.159/032360 PubMed
51. Kohn MR, Madden S, Clarke SD. Refeeding in anorexia nervosa: increased safety and efficiency through understanding the pathophysiology of protein calorie malnutrition. Curr Opin Pediatr. 2011;23(4):390-394. doi:10.1097/MOP.0b013e3283487591 PubMed
52. Attia E, Walsh BT. Behavioral management for anorexia nervosa. N Engl J Med. 2009;360(5):500-506. PubMed
53. Bulik CM, Berkman ND, Brownley KA, et al. Anorexia nervosa treatment: a systematic review of randomized controlled trials. Int J Eat Disord. 2007;40(4):310-320. doi:10.102/eat.20367 PubMed (Pubitemid 46651306)